The extracellular portion of the granulocyte colonystimulating factor (G-CSF) receptor has a mosaic structure of six domains (each approximately 100 amino acid residues) consisting of an immunoglobulin-like (Ig) domain, a cytokine receptor homologous region subdivided into amino-terminal (BN) and carboxyl-terminal (BC) domains, and three fibronectin type III repeats. In the present study, we expressed the Ig-BN and the BN-BC regions and purified them to homogeneity as monomers using G-CSF affinity column chromatography. Using gel filtration high performance liquid chromatography, we investigated the molecular composition of receptor-ligand complexes formed between G-CSF and purified BN-BC or Ig-BN domains. In contrast to the well characterized example of the human growth hormone ( 
Ligand-induced receptor oligomerization has been proposed as the key mechanism of signal transduction for some families of single transmembrane receptors, such as cytokine receptors and tyrosine kinase-type receptors (Ullrich and Schlessinger, 1990; Wells et al., 1993; Heldin, 1995) . In these models, the oligomerization of the extracellular regions, induced by ligand binding, is followed by the activation of their cytoplasmic regions. The extracellular regions of these receptors generally have a composite structure containing multiple domains (Ullrich and Schlessinger, 1990; Bazan, 1990; Miyajima et al., 1992; Heldin, 1995) , which are presumed to play important roles in ligand-induced oligomerization. Investigation of the molecular properties of purified extracellular domains is a prerequisite for understanding mechanisms of receptor oligomerization that culminate in the transductions of external signals.
The extracellular region (ϳ600 amino acid residues) of the granulocyte colony-stimulating factor (G-CSF) 1 receptor is composed of an immunoglobulin-like (Ig) domain, a cytokine receptor homologous (CRH) region, and three fibronectin type III-like domains (Fukunaga et al., 1990b (Fukunaga et al., , 1990c . The Ig domain (ϳ100 amino acid residues) was originally defined by its homology to the immunoglobulin superfamily (Williams and Barclay, 1988) . Though a number of receptors, including those for several cytokines, such as G-CSF, interleukin 6, and ciliary neurotrophic factor, contain Ig domains (Fukunaga et al., 1990b (Fukunaga et al., , 1990c Larsen et al., 1990; Yamasaki et al., 1988 : Davis et al., 1991 , little is known about their function. A deletion derivate of the G-CSF receptor lacking the Ig domain retained ligand binding activity, although the dissociation constant (K d ) value of the mutant was 10 -20-fold higher than that of the intact receptor . The CRH region (ϳ200 amino acid residues) was originally defined by its striking homology to the predicted ligand binding domains of the receptors for various cytokines, such as interleukins 2-7, granulocyte-macrophage colony-stimulating factor, erythropoietin, growth hormone (GH), and prolactin (Bazan, 1990) receptors. The CRH region consists of an amino-terminal (BN; ϳ100 amino acid residues) domain containing four conserved cysteine residues and a carboxyl-terminal (BC; ϳ100 amino acid residues) domain containing a "WSXWS" motif (Bazan, 1990) . Earlier work has identified high affinity oligomers of the G-CSF receptor on the surface of mouse myeloid leukemia cells (Fukunaga et al., 1990a) , and mutational analyses showed that deletion of the BN domain completely abolishes ligand binding activity . As a first step toward studying its molecular properties, we expressed the gene encoding the BN domain as a minimal binding unit, using an Escherichia coli maltose binding protein fusion system (Hiraoka et al., 1994a) . This purified, small domain still retained ligand binding activity but did not form oligomers, such as dimers or tetramers (Hiraoka et al., 1994a) , suggesting that a larger binding unit is required for G-CSF receptor oligomerization. As a second approach, we expressed a three-domain binding unit consisting of Ig-BN-BC regions (ϳ300 amino acid residues; indicated as Ig-CRH in Hiraoka et al. (1994b) ) using an insect Trichoplusia ni cell-baculovirus Autographa californica nuclear polyhedrosis virus system. The purified Ig-BN-BC protein retained high ligand binding activity and formed dimers and tetramers in the presence of G-CSF . These studies indicated the involvement of the Ig or BC regions in receptor oligomerization and suggested that expression of tandem Ig-BN or BN-BC domains might permit functional dissection of the oligomerization process.
In the present study, we describe expression of the Ig-BN and the BN-BC domains of the G-CSF receptor in insect cells using a baculovirus system. Isolated Ig-BN and BN-BC domains did not form homo-oligomers in the presence of ligand, although these products did form 1:1 binary complexes with G-CSF. However, the combined Ig-BN and the BN-BC domains formed a 1:1:1 Ig-BN⅐G-CSF⅐BN-BC complex, which is consistent with binding of a single molecule of G-CSF ligand by a dimeric receptor.
EXPERIMENTAL PROCEDURES

Production of Recombinant Baculoviruses Carrying the Genes Encoding the Ig-BN and the BN-BC Domains of the G-CSF Receptor-The
Ig, BN, and BC domains contain 4, 6, and 4 cysteine residues, respectively (Fukunaga et al., 1990b; Seto et al., 1992) . Since an insect baculovirus A. californica nuclear polyhedrosis virus secretion system has recently been developed for the efficient secretion of such cysteine-rich proteins, (Luckow and Summers, 1988; Ota et al., 1991; Hiraoka et al., 1994b) , the Ig-BN and the BN-BC proteins (each ϳ200 amino acids) were secreted using the recombinant baculoviruses AcIg-BN and AcBN-BC. DNA encoding the murine Ig-BN domain of the G-CSF receptor (Fig. 1A ) and its signal sequence was generated by the polymerase chain reaction amplification of plasmid pBLJ17, which bears the cDNA for the murine G-CSF receptor (Fukunaga et al., 1990b) . The 5Ј-sense primer had the sequence (primer 1) 5Ј-CGGGATCCATGGTAGGGCTGGGAGCCTG-3Ј, which contains a BamHI site (underlined) at the amino terminus, followed by the coding sequence for the murine G-CSF receptor starting from Met
Ϫ25
. The 3Ј-antisense primer has the sequence 5Ј-GCTCTAGATTATTTCACAA-CATCCATGGGGTCGAG-3Ј, which corresponds to the sequence for the carboxyl-terminal part of the Ig-BN domain, terminated at Lys 202 and followed by a stop codon and an XbaI site (underlined). Thus, the resultant fragment contains the signal sequence (Met ) of the murine G-CSF receptor. The fragment was digested with BamHI and XbaI and was used for the construction of the transfer vector, pAcIg-BN.
A DNA fragment corresponding to the BN-BC portion of the murine G-CSF receptor (Fig. 1A ) and its signal sequence was generated from plasmid pBOSdIg, encoding a deletion mutant G⌬(5-84), which lacks Glu 5 -Ser 84 of the Ig domain . To mutate Cys 1 to Ser 1 in the residual portion of the Ig domain of the G⌬(5-84) mutant, two polymerase chain reaction fragments (fragment N and fragment C) were initially generated, using pBOSdIg as the template. Fragment N corresponds to the G-CSF receptor from the amino terminus to Val 85 , including the signal sequence and the deleted part of the Ig domain. Primer 1 above was used for the 5Ј-primer. The 3Ј-antisense primer has the sequence 5Ј-GGACGCCGAT-GTGTCCAGAGCTCTCCAGACTTCTGGGGAG-3Ј, which corresponds to the sequence from Leu Ϫ7 to Ile 4 , and the anti-codon Val
85
, in which the anticodon ACA for Cys 1 was replaced with AGA (underlined) for Ser. Fragment C corresponds to the sequence from Leu Ϫ3 to Ala 309 of the deletion mutant cDNA G⌬(5-84), followed by a stop codon. The 5Ј-primer has the sequence 5Ј-CTGGAGAGCTCTGGACACATCGGCGTCCAACTCCTG-3Ј, which contains the coding sequence from Leu Ϫ3 to Ile 4 and from Val 85 to Ala 309 , in which the codon TGT for Cys 1 was replaced with TCT (underlined) for Ser. The 3Ј-antisense primer (primer 2) has the sequence 5Ј-GCTCTA-GATTAGGCCTTCATGGTAGGCCTCA-3Ј, which corresponds to the sequence for the carboxyl-terminal part of the BN-BC domain, terminated at Ala 309 and followed by a stop codon and an XbaI site (underlined). To amplify the full-length BN-BC DNA, small amounts of fragments N and C were used as the template for a second round of the polymerase chain reaction, using primer 1 as the 5Ј-primer and primer 2 as the 3Ј-primer, respectively. Thus, the resulting fragment contains the signal sequence (Met ) of the murine G-CSF receptor. After digestion with BamHI and XbaI, the resultant fragment was used for the transfer vector, pAcBN-BC.
The transfer vectors pAcIg-BN and pAcBN-BC were obtained by the insertion of these amplified DNA fragments within the BamHI/XbaI sites of plasmid pVL1393 (Invitrogen), which carries part of the genome of the A. californica nuclear polyhedrosis virus. The BamHI/XbaI sites in pVL1393 are downstream of the polyhedrin promoter. The recombinant viruses AcIg-BN and AcBN-BC, carrying the Ig-BN and the BN-BC genes, were produced by in vivo homologous DNA recombination using the transfer vectors pAcIg-BN and pAcBN-BC, as described (Summers and Smith, 1988; Ota et al., 1991 TM cells) were infected with recombinant viruses and were cultured for 9 days at 18°C. The culture fluids were applied to a G-CSF affinity column (1 cm, inner diameter, ϫ 5 cm), and the Ig-BN and the BN-BC proteins were eluted by a glycine-HCl, pH 2.0, buffer. The affinity-purified proteins were then chromatographed by gel filtration high performance liquid chromatography (HPLC) (7.6 mm, inner diameter, x 60 cm; TSKgel G3000SW; TOSO Co., Ltd) as described . For further purification, the Ig-BN fraction was applied to a DEAE HPLC column (4.6 mm, inner diameter, ϫ 25 cm; TSKgel DEAE-2SW; TOSO Co., Ltd) equilibrated with 20 mM sodium phosphate buffer, pH 6.0. Ig-BN was eluted with a linear gradient of NaCl from 0 to 0.4 M.
G-CSF Binding to the Ig-BN and the BN-BC Domains of the G-CSF Receptor-
The assay used to quantitate G-CSF binding to the BN-BC domain of the G-CSF receptor was essentially that described by Fukunaga et al. (1990a) . The BN-BC domain was mixed with various concentrations (10 pM to 1 nM) of 125 I-labeled G-CSF (Amersham International plc) in 50 l of phosphate-buffered saline containing 10% fetal calf serum and 0.1% Chaps in the presence or absence of 500 nM unlabeled G-CSF. The binding reaction proceeded for 90 min at room temperature. After the incubation, the BN-BC portion of the G-CSF receptor⅐G-CSF complex was precipitated with carrier protein (␥-globulin) and anti-M1 serum specific for the CRH region of the G-CSF receptor by 15% (w/v) polyethylene glycol 6000. The radioactivity in the precipitate was measured using a ␥-counter (Packard, AUTO-GAMMA model A5002 COBRA). The 125 I-G-CSF binding assays used to establish the complexes of the Ig-BN or the BN-BC domains of the G-CSF receptor with G-CSF were performed by means of gel filtration HPLC, as described .
Production and Purification of the BN-BC Domain of the GH Receptor-
The BN-BC domain of the human GH receptor corresponds to its entire extracellular region (Bazan, 1990) . Production and purification of the BN-BC domain of the GH receptor, using the insect baculovirus system, were performed according to the procedure described for the extracellular region of the human GH receptor (Ota et al., 1991) . In the present study, the DNA sequence encoding Met
Ϫ18
-Leu 233 of the human GH receptor (Leung et al., 1987) followed by a stop codon, TAA, comprised the BN-BC domain sequence of the GH receptor.
RESULTS
Expression and Purification of the Ig-BN Protein-
The purified Ig-BN protein migrated as a homogeneous 33-kDa band during polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) (Fig. 1B) . Western blotting using anti-M1 serum specific for the CRH region of the G-CSF receptor identified the same 33-kDa band (Fig. 1B) . Furthermore, the amino-terminal amino acid sequence of the purified 33-kDa protein ((Cys)-Gly-His-Ile-GluIle-), identified by direct sequencing on an automated gas phase sequencer (Applied Biosystems 477A sequencer equipped with a model 120A PTH analyzer), corresponded precisely to that of the amino terminus of the G-CSF receptor, as deduced from the murine G-CSF receptor sequence (Fukunaga et al., 1990b; Hiraoka et al., 1994b) . These results confirmed that the purified product was the Ig-BN protein. The position of the eluted peak at 35 kDa by gel-filtration HPLC indicated that the purified Ig-BN protein existed as a monomer. Approximately 50 g of the purified Ig-BN protein was obtained per liter of culture.
The molecular mass of the Ig-BN protein, identified by SDS-PAGE and gel-filtration HPLC, is larger than the molecular mass of 23 kDa deduced from the Ig-BN protein sequence (Cys 1 -Lys 202 ) (Fukunaga et al., 1990b; Seto et al., 1992) . The discrepancy between the observed and predicted molecular masses is most likely due to glycosylation. The Ig-BN protein has three potential Asn-linked glycosylation sites, which are conserved between the murine and human G-CSF receptors (Fukunaga et al., 1990b (Fukunaga et al., , 1990c . The 33-kDa band identified by Western blotting of the culture fluid was not detected when tunicamycin, a glycosylation inhibitor, was added to the culture medium after infection, supporting the proposed glycosylation of the Ig-BN protein. When Western blotting of the culture fluid was performed under nonreducing conditions, we noted that the 33-kDa band was less abundant and that most anti-M1 reactive material migrated at more than 100 kDa. Presumably, most native Ig-BN molecules are secreted into the culture fluid as large molecular weight aggregates due to the effects of random disulfide bond formation, and only the 33-kDa monomeric form, which bound to the G-CSF affinity column, was purified. The far UV CD spectrum of the Ig-BN protein ( Fig.  2A) exhibited positive ellipticity at 230 nm and negative ellipticity around 210 nm. The extracellular region of the human GH receptor (Fig. 2D) (Bass et al., 1991) showed a very similar CD spectrum, suggesting that the purified Ig-BN protein has a GH receptor-like structure. These results are consistent with the spectra of the Ig-BN-BC region ( Fig. 2C ; Hiraoka et al., 1994b) and the BN domain (Hiraoka et al., 1994a) .
Expression and Purification of the BN-BC Protein-To purify the BN-BC protein, we used the recombinant baculovirus AcBN-BC, which was constructed from the plasmid pBOSdIg, harboring the mutated murine cDNA G⌬(5-84). G⌬(5-84) encodes the BN-BC portion but lacks most of the Ig domain. The G⌬(5-84) mutant receptor was shown to retain significant ligand binding activity when expressed on the surface of mammalian cells, despite the absence of an intact Ig region . The G⌬(5-84) mutation removes all but 16 amino acid residues (Cys ), based on the exon-intron organization of the G-CSF receptor gene (Seto et al., 1992; Hiraoka et al., 1994b) . In the construction of the recombinant baculovirus AcBN-BC, we replaced Cys (Fukunaga et al., 1990b) . The Ig, BN, and BC domains correspond approximately to exon 4, exons 5 and 6, and exons 7 and 8, respectively (Seto et al., 1992) . The thin bars in the G-CSF receptor represent the conserved cysteine residues, and the thick bar represents the conserved WSXWS motif. Numbers indicate the amino acid number of the G-CSF receptor. B and C, 0.1% SDS-12.5% PAGE and Western blotting of the Ig-BN protein eluate from the TSKgel DEAE-2SW HPLC and the BN-BC protein eluate from the TSKgel G3000 SW gel filtration HPLC, respectively. The SDS-PAGE gels were stained with Coomassie Brilliant Blue (CBB). Western blotting was performed using anti-M1 serum as described . The numbers show the sizes (in kDa) of the marker proteins in lane M.
FIG. 2.
Far-UV CD spectra of the Ig-BN, the BN-BC, and the Ig-BN-BC regions of the G-CSF receptor and the BN-BC portion of the GH receptor. The CD spectrum was measured on a Jasco J-720 spectropolarimeter (Japan Spectroscopic Co., Ltd.) at 20°C with solutions in 10 mM sodium phosphate buffer (pH 6.0) containing 0.093 mg/ml Ig-BN protein (A), 0.11 mg/ml BN-BC protein (B), and 0.12 mg/ml of Ig-BN-BC protein (C) of the G-CSF receptor and 0.10 mg/ml of the BN-BC protein of the GH receptor (D; indicated as hGH-R; Ota et al., 1991) . The optical path length was 1 mm for the far ultraviolet CD spectra. (Goodwin and Morton, 1946) . (Fig. 1C) . These data strongly suggested that the purified product corresponds to a BN-BC protein monomer. The molecular masses of 32 kDa (SDS-PAGE) and 27 kDa (gel filtration) of the purified BN-BC protein appear larger than the molecular mass of 24 kDa deduced from the predicted BN-BC protein sequence (Ala 95 -Ala 309 ) (Fukunaga et al., 1990b; Seto et al., 1992) . However, the BN-BC protein has one potential Asn-linked glycosylation site (Fukunaga et al., 1990b (Fukunaga et al., , 1990c The far UV CD spectrum of the BN-BC protein (Fig. 2B ) was similar to those of the Ig-BN domain and the human GH receptor (Fig. 2D) (Bass et al., 1991) , suggesting that the BN-BC protein also has a GH receptor-like structure. The amino-terminal sequence of the purified BN-BC protein was determined. The predominant amino-terminal residue was Ala, followed by the sequence Gly-Tyr-Pro-Pro. This amino-terminal residue corresponds to Ala 95 of the Ser ) derived from the Ig region. A minor (less than 10%, as estimated by gel filtration HPLC), contaminating amino-terminal residue was Asp, followed by the sequence Gln-Ala-Glu-Leu. This aminoterminal residue corresponds to Asp 89 of the 16 residual amino acids from the Ig domain. Thus, the expressed BN-BC protein contains the amino terminus expected of the BN-BC domain; however, most of the short Ig-derived sequence was removed during or after the processing of the signal peptide. As a control, we expressed the BN-BC domain from Tyr 97 to Ala 309 using an E. coli maltose binding protein fusion system, as described (Hiraoka et al., 1994a) . The E. coli purified BN-BC domain exhibited almost the same K d for G-CSF and the same CD spectrum as those of the purified BN-BC domain expressed using the baculovirus system. 2 These results suggested that the residual 16 amino acids of the Ig domain affect neither the K d nor the conformation of the BN-BC domain.
Formation of the BN-BC⅐G-CSF and the Ig-BN⅐G-CSF Binary Complexes and the Ig-BN⅐G-CSF⅐BN-BC Ternary
Complex-To analyze the effect of the ligand G-CSF upon oligomerization of purified BN-BC protein, the size of the purified BN-BC⅐G-CSF (27 and 19 kDa, respectively) complex was established by separating mixtures of the proteins (in ratios of BN-BC:G-CSF; 1:5, 1:1, 1:0.5, 1:0.1, and 1:0) by gel filtration HPLC (Fig. 3) . At a 1:1 ratio of BN-BC to G-CSF, virtually all of the protein chromatographed at the position corresponding to a molecular mass of 35 kDa (Fig. 3, line 2 , and Table I ). When the ratio of the BN-BC protein to G-CSF was 1:5, an excess of free G-CSF (19 kDa) appeared as a peak (Fig. 3, line 1) . The 35-kDa peak did not dissociate, and no peak with a higher molecular mass was detected (Fig. 3, line 1) . When the ratio was below 1:1 (ratios of 1:0.5, 1:0.1, and 1:0), a BN-BC (27 kDa) peak was present, whereas free G-CSF was absent (Fig. 3, lines  3 -5) . Gel filtration of the BN-BC⅐G-CSF complex using 125 I-G-CSF confirmed that most of the 125 I-G-CSF chromatographed at the position corresponding to 35 kDa at an extremely low concentration of the ligand (1:0.0004 ratio of BN-BC to G-CSF), whereas most of this 125 I-G-CSF migrated at the position corresponding to 19 kDa in the presence of a high concentration of the unlabeled ligand (1:4 ratio of BN-BC to G-CSF) (data not shown). Thus, these data indicated that the BN-BC domain of the G-CSF receptor formed a stable 1:1 complex with G-CSF. The mass of the observed complex, 35 kDa, was somewhat smaller than the 46-kDa mass calculated from the sum of the components (Table I) . However, gel filtration HPLC analysis of the BN-BC domain expressed using an E. coli system also gave a smaller apparent mass for the BN-BC⅐G-CSF complex.
2 Fuh et al. (1990) expressed the BN-BC portion of the GH receptor as a soluble protein using an E. coli secretion system. The molecular composition of the BN-BC portion of the GH receptor⅐GH complex established by gel filtration HPLC showed a stoichiometry of 2:1 (Cunningham et al., 1991) . As a control to test the accuracy of our gel filtration assessment of molecular mass, we also expressed the BN-BC portion of the GH receptor using the insect-baculovirus system and at-2 O. Hiraoka, H. Anaguchi, and Y. Ota, manuscript in preparation. 0.1% values of 2.2 and 0.81, respectively) as described in Fig. 2 . Protein mixtures were equilibrated for 90 min at 20°C in 20 mM sodium phosphate buffer (pH 7.0) containing 0.2 M NaCl. Samples (200 l) were applied to a TSKgel G3000SW gel filtration HPLC (7.6 mm, inner diameter, ϫ 60 cm; TOSO Co., Ltd) and were eluted with the same buffer at 0.5 ml/min. Peaks were monitored for absorbance at 280 nm. The elution positions of the BN-BC portion of human GH receptor, the human GH, and their complexes estimated from Table I tempted to induce the formation of the 2:1 receptor⅐ligand complex. At a 1:0.5 ratio of the BN-BC portion of the GH receptor to GH, all of the protein chromatographed as a single peak, which corresponded to an 82-kDa complex composed of two molecules of the BN-BC portion of the GH receptor (30 kDa)/molecule of GH (22 kDa) (Fig. 4, line 3) . When the ratio of the GH receptor to GH was decreased, a peak appeared corresponding to a 1:1 complex of 52 kDa, and the 82-kDa peak decreased in size (Fig. 4, lines 1 and 2) . These results confirmed that a 2:1 GH receptor to GH complex was formed, and this complex dissociated to the 1:1 complex with an excess of GH, as described (Cunningham et al., 1991; de Vos et al., 1992; Fuh et al., 1992) . These results also indicated that the stoichiometry of the receptor BN-BC⅐ligand complex differs between the G-CSF and the GH receptors, despite the structural similarity between their BN-BC domains.
The Ig-BN (35-kDa) complex with G-CSF (19 kDa) was also established using gel filtration HPLC (Fig. 5) . At a 1:1 ratio of Ig-BN to G-CSF, all of the protein chromatographed at 48 kDa (Fig. 5, line 2) , corresponding to the size of a 1:1 complex (Table  I) . When the ratio of Ig-BN to G-CSF was 1:10, peaks corresponding to the 1:1 complex, as well as to free G-CSF, were present, and no peaks with higher or lower molecular masses were detected (Fig. 5, line 3) . These results show that the Ig-BN protein formed a stable 1:1 complex with G-CSF. When the Ig-BN protein was mixed with the BN-BC protein in addition to G-CSF, a peak of 74 kDa appeared, with a corresponding decrease in the 48-kDa peak (in ratios of Ig-BN:G-CSF:BN-BC; 1:1:0, 1:1:0.5, 1:1:3; Fig. 5, lines 2, 4, and 5 ). This result is consistent with the formation of a 1:1:1 Ig-BN⅐G-CSF⅐BN-BC complex, as the observed molecular mass of 74 kDa is quite close to the expected mass of 81 kDa for a 1:1:1 ternary complex (Table I) . Components of the ternary complex were confirmed by analysis of amino-terminal residues released from the 74-kDa peak (data not shown). No Ig-BN⅐BN-BC complex was formed in the absence of G-CSF (Fig. 5, line 6 ). The 35-kDa peak that would correspond to release of the Ig-BN domain was not detected by gel filtration HPLC, either upon addition of a small (1:1:0.5 ratio; Fig. 5, line 4) or an excess amount (1:1:3 ratio; Fig. 5, line 4) of the BN-BC domain. G-CSF was detected only in the 74-kDa peak seen upon addition of an excess amount of the BN-BC domain (1:1:3 ratio; Fig. 5 , line 5; Western blotting; data not shown). These results suggested that the BN-BC protein did not compete with the Ig-BN protein for binding to G-CSF. The formation of the 74-kDa peak and the retention of the Ig-BN domain in the complex were confirmed by the addition of an excess amount of the BN-BC domain to the purified Ig-BN⅐G-CSF complex, using gel filtration HPLC (data not shown).
DISCUSSION
The BN-BC domain of the human GH receptor forms a 2:1 receptor⅐ligand complex with the GH ligand, with consequent dimerization of the GH receptor (Cunningham et al., 1991; de Vos et al., 1992) . We confirmed the existence of this 2:1 complex using GH receptor produced by a baculovirus system. Similar 2:1 receptor-ligand complexes have also been obtained using the receptors for interferon-␥ and prolactin (Greenlund et al., 1993; Hooper et al., 1993) . Among the members of the cytokine receptor family, these receptors, as well as the G-CSF receptor, seem to function as homo-oligomers Hiraoka et al., 1994b) , supporting the view that the BN-BC domain of the G-CSF receptor may form a 2:1 receptorligand complex. Surprisingly, however, we found that the BN-BC domain of the G-CSF receptor forms a 1:1 binary complex with its ligand G-CSF, suggesting that the BN-BC domain of the G-CSF receptor alone is not sufficient for G-CSF-induced a The observed molecular masses of the BN⅐G-CSF, BN-BC⅐G-CSF, and Ig-BN⅐G-CSF⅐BN-BC complexes were estimated using the TSKgel G3000SW gel filtration HPLC, as described in Figs. 3 and 5. The 2:1 (82-kDa) and the 1:1 (52-kDa) complexes of the BN-BC portion of the human GH receptor to human GH were formed as described in Fig. 4 , and the BN-BC portion of the human GH receptor (30 kDa; Ota et al., 1991) , and the human GH (22 kDa; recombinant GH produced by the E. coli system) (Ota et al., 1991) were used as molecular size markers.
b The calculated molecular masses of the BN-BC⅐G-CSF, Ig-BN⅐G-CSF, and Ig-BN⅐G-CSF⅐BN-BC complexes were estimated by the summation of the apparent molecular mass of each component; the BN-BC (27-kDa) and Ig-BN (35-kDa) domains of the G-CSF receptor, and human G-CSF (19 kDa; recombinant G-CSF produced by the E. coli system; Kirin Brewery Co., Ltd). The apparent molecular masses of the BN-BC and Ig-BN domains were determined by TSKgel G3000SW gel filtration HPLC, using the molecular size markers described above. Ota et al., 1991) were calculated from the absorption at 280 nm (A 280 0.1% values of 2.3 and 0.80, respectively) as described in Fig. 2 . Protein mixtures were equilibrated for 90 min at 20°C in 20 mM sodium phosphate buffer (pH 7.0) containing 0.2 M NaCl. Samples (200 l) were applied to the TSKgel G3000SW gel filtration HPLC and were eluted with the same buffer at 0.5 ml/min. Peaks were monitored for absorbance at 280 nm. The elution positions of bovine serum albumin (BSA; 67 kDa) and ovalbumin (ova; 43 kDa) are indicated by arrows.
oligomerization. Notably, extracellular portions of the receptors for GH, interferon-␥, and prolactin compose only the BN-BC region (Bazan, 1990) , while the G-CSF receptor contains Ig and fibronectin type III domains in addition to the BN-BC functional unit. In a previous study, we demonstrated that the purified Ig-BN-BC protein existed as dimeric or tetrameric forms in the presence of G-CSF . These results suggested the possibility that the Ig domain might play an important role in oligomerization of the G-CSF receptor.
Cunningham et al. indicated that the GH receptor contains two overlapping binding sites that interact with two distinct sites on the GH protein, thereby producing the 2:1 receptorligand complex (Cunningham et al., 1991) . In contrast, our results suggest that the BN-BC region of the G-CSF receptor contains a single binding site for G-CSF, while the Ig domain may provide a second ligand binding site. The purified Ig-BN protein formed a stable 1:1 binary complex, indicating that the Ig-BN region is also able to contribute to stable binding of G-CSF. Furthermore, we detected the formation of a 1:1:1 Ig-BN⅐G-CSF⅐BN-BC ternary complex upon addition of BN-BC protein to the 1:1 Ig-BN⅐G-CSF complex. These results suggested that two binding sites for G-CSF are found within the Ig-BN-BC region and that, unlike the GH receptor paradigm, two different functional units of the receptor molecule (both BN-BC and Ig-BN) are involved in interactions with two distinct binding sites on the G-CSF ligand.
The apparent K d of the BN-BC domain for G-CSF in the present study is about 2.5 ϫ 10 Ϫ9 M. This value is similar to the K d of about 3.7 ϫ 10 Ϫ9 M exhibited by the deletion mutant of the G-CSF receptor expressed on the surface of a murine myeloid cells that contains both the BN and the BC domains but lacks the Ig domain . We could not measure the K d of the Ig-BN domain for G-CSF, because of the low purification yield and weak affinity of the anti-G-CSF receptor CRH antibody (anti-M1 serum; Fukunaga et al., 1991) Ϫ8 M for a mutant G-CSF receptor expressing the Ig and BN domains in addition to the fibronectin type III domains but lacking the BC domain at the cell surface . Thus, it is likely that the affinity of the BN-BC domain for G-CSF is higher than that of the Ig-BN domain. Interestingly, in our study the Ig-BN domain was not released when the BN-BC domain was incubated with the Ig-BN⅐G-CSF complex. This finding is consistent with the idea that the binding site on the Ig-BN domain is distinct from that of the BN-BC domain. We have reported previously that the expressed Ig-BN-BC protein was purified primarily as a dimer, using G-CSF affinity column chromatography, and that only the dimeric Ig-BN-BC protein retained affinity for the ligand, termed "high" affinity (K d ϭ about 10 Ϫ10 M), while the monomeric Ig-BN-BC protein showed reduced affinity, which was termed "low" (K d ϭ about 2.5 ϫ 10 Ϫ9 M) . These data supported the proposal that the Ig-BN-BC protein has two binding sites and suggested that the two sites provided by each dimeric Ig-BN-BC chain are required for high affinity binding of G-CSF. The apparent K d of the purified BN-BC domain (about 2.5 ϫ 10 Ϫ9 M) is nearly the same as that exhibited by the monomeric Ig-BN-BC protein and corresponds to low affinity ligand binding .
In our previous work, we indicated that the Ig-BN-BC⅐G-CSF complex was composed of a dimeric Ig-BN-BC protein which forms at an extremely low concentration of G-CSF, and that this dimer converted to a tetramer with an increase in the concentration of ligand . The stoichiometry of the tetrameric complex was determined to be 4:4 Ig-BN-BC⅐G-CSF . We could not estimate the stoichiometry of the dimeric complex in that study because of the extremely low yield. In the present study, we did not obtain any receptor-ligand complexes containing four molecules of receptor (such as a 2:2:2 or 2:4:2 Ig-BN⅐G-CSF⅐BN-BC complexes, which would correspond to a 4:2 or 4:4 receptor-ligand stoichiometry), even at a high concentration of G-CSF (data not shown). These data suggest that a minimal Ig-BN-BC functional unit is required for the tetramerization. Fuh et al. expressed chimeric GH and G-CSF receptor cDNAs in a leukemia cell line and showed that the 2:1 GH receptor-GH complex, induced at a low concentration of GH, was the active form for signal transduction, whereas the 1:1 complex, induced at a high concentration of GH, was an inactive form (Fuh et al., 1992) . Thus, it is likely that the receptor-ligand complex identified in the present study was "frozen" during purification as 2:1 G-CSF receptor-G-CSF stoichiometry, which appeared as a 1:1:1 Ig-BN-BC⅐G-CSF⅐BN-BC ternary complex (Fig. 6) . The possibility remains that the G-CSF receptor exists on the cell surface as a dimer and that higher molecular weight aggregates, e.g. tetramers, constitute the activated form of the receptor induced by G-CSF stimulation (Fukunaga et al., 1990a; Hiraoka et al., 1994b) . However, identification of a 1:1:1 Ig-BN⅐G-CSF⅐BN-BC ternary complex, formed by two discrete values of 1.3, 2.2, and 0.81, respectively) as described in Fig. 2 . Protein mixtures were equilibrated for 90 min at 20°C in 20 mM sodium phosphate buffer (pH 7.0) containing 0.2 M NaCl. Samples (200 l) were applied to the TSKgel G3000SW gel filtration HPLC and were eluted with the same buffer at 0.5 ml/min. Peaks were monitored for absorbance at 280 nm. The elution positions of the BN-BC portion of human GH receptor, the human GH, and their complexes estimated from Table  I are indicated by arrows.
ligand binding sites in separate functional domains, suggests that the formation of a 2:1 G-CSF receptor-ligand complex may play an important role in the function of the G-CSF receptor, even if the dimerization of the G-CSF receptor is insufficient to activate the receptor. Interestingly, a mutant G-CSF receptor (G⌬(5-84)) containing the BN-BC and fibronectin type III domains but lacking the Ig domain still retains weak signal transduction activity . Thus, if the activated form of the G-CSF receptor is indeed a dimer, it is likely that high concentrations of G-CSF can drive the G⌬(5-84) mutant receptor into a dimeric form, at least to some extent, even in the absence of the Ig domain. The mechanism and the meaning of the conversion from dimeric to tetrameric forms of the G-CSF receptor are still open questions. Further studies, including both mutational and structural analyses, are required to understand the precise mechanism of oligomerization and to correlate the observed oligomerization in solution to the mitogenicity of G-CSF.
